Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis

Br J Haematol. 1994 Feb;86(2):391-3. doi: 10.1111/j.1365-2141.1994.tb04748.x.

Abstract

Serum bioactive but not immunoreactive interleukin-6 (IL-6), and serum C-reactive protein (CRP), have been reported to be of prognostic significance in multiple myeloma (MM). We measured serum immunoreactive IL-6 by a sensitive enzyme-linked immunosorbent assay in 30 MM patients at diagnosis. In 30% of the patients serum immunoreactive IL-6 exceeded the upper reference limit. The concentrations of CRP and IL-6 showed a linear association. Logarithmically transformed IL-6, CRP and beta 2-microglobulin were significant variables by univariate survival analysis; by multivariate analysis CRP was a slightly stronger prognostic factor than IL-6 and the only one of independent prognostic significance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood*
  • C-Reactive Protein / analysis*
  • Female
  • Follow-Up Studies
  • Humans
  • Interleukin-6 / blood*
  • Interleukin-6 / immunology
  • Male
  • Middle Aged
  • Multiple Myeloma / blood*
  • Multiple Myeloma / mortality
  • Prognosis

Substances

  • Biomarkers, Tumor
  • Interleukin-6
  • C-Reactive Protein